A Robert D Bailey
CIK 1591683 · EVP & Chief Legal Officer · last filed 2026-08-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BLCO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
909 THIRD AVENUE
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BLCO | EVP & Chief Legal Officer | 264,241 | $17.37 | $4.59M | $250.3K | 13 | 2026-08-07 |
| Allergan plc (AGN) Delisted | EVP Chief Legal Off & Corp Sec | 0 | — | — | $0 | 15 | 2020-05-11 |
| ACT | Chief Legal Officer & Corp Sec | 16,918 | $46.75 | $790.9K | $0 | 2 | 2015-05-19 |
| Forest Laboratories, LLC (FRX) Delisted | SVP Chief Legal Off, GC & Sec | 0 | $12.00 | $0 | $0 | 2 | 2014-07-02 |
Recent Filings · Page 3 of 4
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-01-02 | Allergan plc (AGN) Delisted | Tax (F) | −1,136 | -$185.8K | EDGAR |
| 2017-10-30 | Allergan plc (AGN) Delisted | Mixed | +7,992 | $1.0K | EDGAR |
| 2017-05-16 | Allergan plc (AGN) Delisted | Tax (F) | −456 | -$104.1K | EDGAR |
| 2017-04-04 | Allergan plc (AGN) Delisted | Grant (A) | +5,890 | $1.40M | EDGAR |
| 2016-11-15 | Allergan plc (AGN) Delisted | Tax (F) | −702 | -$145.7K | EDGAR |
| 2016-07-05 | Allergan plc (AGN) Delisted | Tax (F) | −2,947 | -$681.0K | EDGAR |
| 2016-05-17 | Allergan plc (AGN) Delisted | Tax (F) | −491 | -$109.7K | EDGAR |
| 2015-11-16 | Allergan plc (AGN) Delisted | Tax (F) | −565 | -$169.5K | EDGAR |
| 2015-05-19 | ACT | Tax (F) | −499 | -$148.0K | EDGAR |
| 2015-03-31 | ACT | Grant (A) | +7 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.